Cited by 286Breast Cancer Treatment StudiesCancer survivorship and careMenopause: Health Impacts and Treatments

The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.

Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy

Open access

Cella, David, Fallowfield, Lesley J.·2008·Breast Cancer Research and Treatment

Open this paper in CoChat — free account

Abstract

In postmenopausal women with hormone receptor-positive early-stage breast cancer, the use of aromatase inhibitors (AIs) to suppress estrogen is associated with improved clinical outcomes compared with tamoxifen therapy. Women receiving such endocrine therapy may experience treatment-related side effects that negatively affect health-related quality of life (QoL) and adherence to therapy. In published clinical trials and in clinical practice, adverse events (AEs) constitute the main reason for nonadherence to endocrine treatment. Serious AEs are sometimes resolved by switching to a different agent, whereas other side effects can often be managed to allow patients to remain on therapy without sacrificing QoL. Across all adjuvant endocrine trials, regardless of the treatment received, vasomotor symptoms such as hot flashes are the most common side effects. Other frequently reported side effects, such as vaginal discharge, vaginal dryness, dyspareunia, and arthralgia, vary in prevalence between tamoxifen and AIs. Here we provide an overview of reported AEs of adjuvant endocrine therapy, focusing on those that are amenable to pharmacologic or nonpharmacologic management without treatment discontinuation. Also highlighted are specific management strategies that may improve patient QoL and thereby optimize adherence to therapy, which in turn might improve patient outcomes.

Integrity signals

Registry

Crossref · 10.1007/s10549-007-9548-1

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

RETRACTED: Drug-induced lupus erythematosus
Sarzi‐Puttini, P., Atzeni, F., Sarzi‐Puttini, P., Atzeni, F., CAPSONI, F., Sarzi‐Puttini, P., Atzeni, F., CAPSONI, F., Lubrano, E., Sarzi‐Puttini, P., et al. (2005) · Autoimmunity · doi:10.1080/08916930500285857 · Cited by 125
Retracted
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284 · cited 1×
“Conversely, the systemic estrogen deprivation that results from AI therapy in postmenopausal women can result in bone resorption and osteoporosis, with higher fracture rates [2, 4, 7].”
Background
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Baum, M., Budzar, A. U., Cuzick, J. M., Forbes, J., Houghton, J., Klijn, J. G. M., & Sahmoud, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09088-8 · Cited by 1,958
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Self-citation
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
The Breast International Group (BIG) 1-98 Collaborative Group (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052258 · Cited by 1,584
Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M. M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji250 · Cited by 1,116 · cited 3×
“005), suggesting inhibition of endometrial proliferation by the AI [7].”
BackgroundMethodInfluential
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004
Winer, E. P., Hudis, C. A., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., Chlebowski, R. T., Gelber, R. D., Edge, S. B., Gralow, J. R., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.121 · Cited by 1,026
Transdermal testosterone treatment in women with impaired sexual function after oophorectomy.
Shifren, J. L., Braunstein, G. D., Simon, J. A., Casson, P. R., Buster, J. E., Redmond, G. P., Burki, R. E., Ginsburg, E. S., Rosen, R. C., Leiblum, S. R., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009073431002 · Cited by 954 · cited 1×
“Loss of libido Better patient/physician communication Transdermal testosterone Shifren et al. [ 66 ]”
Background
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
Jin, Y., Desta, Z., Stearns, V., Ward, B. A., Ho, H., Lee, K.-H., Skaar, T. C., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951

Show all 83 references

Research works printed but not linked: 4

Taylor M, Rastelli A, Civitelli R et al (2004) Incidence of 25-OH vitamin D deficiency in patients with a history of breast cancer who have musculoskeletal symptomatology. Abstract presented at the 27th Annual San Antonio Breast Cancer Symposium; December 8–11, 2004; San Antonio, TX
Thompson JN, Napoli N, Civitelli R et al (2006) Effects of dietary calcium vs. calcium supplements on estrogen metabolism and bone density. Osteoporos Int 17:S205 (abstract P696MO)
Plourde P, Locker G, Hoctin-Boes G et al (2005) Arthralgia in postmenopausal breast cancer patients on adjuvant endocrine therapy: a risk-benefit analysis. Poster presented at: 7th Annual Lynn Sage Breast Cancer Symposium; October 6–9 2005; Chicago, Illinois
Mok K, Mireskandari S, Juraskova I et al (2006) OVER (Olive oil Vaginal Exercises and Replens) Come. Psycho-Oncology 15:S332 (abstract 778)

Sorted by citations

Items 201–286 of 286

Evaluation of a novel strategy to implement exercise evidence into clinical practice in breast cancer care: protocol for the NEXT-BRCA randomised controlled trial
Smith‐Turchyn, J., Mukherjee, S. D., Richardson, J. A., Ball, E., Bordeleau, L. J., Neil‐Sztramko, S., Levine, O. H., Thabane, L., Sathiyapalan, A., & Sabiston, C. M. (2020) · BMJ Open Sport & Exercise Medicine · doi:10.1136/bmjsem-2020-000922 · Cited by 6
Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer
Adachi, Y., Oze, I., Sawaki, M., Hattori, M., Yoshimura, A., Kotani, H., Kataoka, A., Sugino, K., Horisawa, N., Ozaki, Y., et al. (2021) · Breast Cancer · doi:10.1007/s12282-021-01245-w · Cited by 7
“These adverse events have been reported to affect quality of life of patients [11, 12].”
Background
Promoting Self-management and Patient Activation Through eHealth: Protocol for a Systematic Literature Review and Meta-analysis
Moradian, S., Maguire, R., Liu, G., Krzyzanowska, M. K., Butler, M. O., Cheung, C. C., Signorile, M., Gregorio, N., Ghasemi, S., & Howell, D. (2022) · JMIR Research Protocols · doi:10.2196/38758 · Cited by 6
Adherence Rates and Correlates in Long-term Hormonal Therapy
Dunn, J., & Gotay, C. C. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-416673-8.00003-4 · Cited by 7
Association between Health-Related Quality of Life and Completion of First-Line Treatment among Lung Cancer Patients
Levinsen, A. K. G., Dalton, S. O., Andersen, I., Mellemgaard, A., Oksen, M. S., Saltbæk, L., Hansen, N. H. G., Carlsen, S., & Kjær, T. K. (2022) · Cancers · doi:10.3390/cancers14143343 · Cited by 5
“Other studies show that the association between HRQOL and cancer survival may partly be explained by a psychosocial connection, in which poor HRQOL is associated with lack of adherence to treatment plans [7,13,14].”
Background
Decision-making in the multiphase optimization strategy: Applying decision analysis for intervention value efficiency to optimize an information leaflet to promote key antecedents of medication adherence
Green, S. M. C., Smith, S. G., Collins, L. M., & Strayhorn, J. C. (2024) · Translational Behavioral Medicine · doi:10.1093/tbm/ibae029 · Cited by 5
“However, maintaining adherence to AET can be challenging, e.g. due to side-effects such as hot flushes and joint pains, which are commonly reported in women taking AET [18].”
Background
Predictors of Work-Related Disability During Early Phases of Breast Cancer Treatment
Brick, R. S., Skidmore, E. R., Terhorst, L. A., McCue, M. P., & Bender, C. (2019) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0000000000001138 · Cited by 6
Demystifying breast cancer
Wilkinson, A. N. (2023) · Canadian Family Physician · doi:10.46747/cfp.6907473 · Cited by 5
Factorial Trial to Optimize an Internet-Delivered Intervention for Sexual Health After Breast Cancer: Protocol for the WF-2202 Sexual Health and Intimacy Enhancement (SHINE) Trial
Shaffer, K. M., Reese, J. B., Dressler, E. V. M., Glazer, J. V., Cohn, W. F., Showalter, S. L., Clayton, A. H., Danhauer, S. C., Loch, M. M., Kadi, M. S., et al. (2024) · JMIR Research Protocols · doi:10.2196/57781 · Cited by 4
“…induce menopause with more severe symptoms [8-10]; take adjuvant endocrine therapy (AET; tamoxifen or aromatase inhibitors) as it blocks estrogen [11-13]; have comorbid depression and anxiety [14-16]; and have newer relationships or are generally more dissatisfied in their relationship [5,17-19].”
Background
Long-Term Adherence to Adjuvant Endocrine Therapy Following Various Radiotherapy Modalities in Early Stage Hormone Receptor Positive Breast Cancer
Ward, K. A., Muller, D. A., Dutta, S. W., Malhi, J. K., Sanders, J. C., Luminais, C., Millard, T. A., Showalter, T. N., Showalter, S. L., & Janowski, E. (2023) · Clinical Breast Cancer · doi:10.1016/j.clbc.2023.01.012 · Cited by 4
Quality of Life Issues During Adjuvant Endocrine Therapy
Fallowfield, L. J., & Jenkins, V. A. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-75115-3_22 · Cited by 4
“Finally, we need to invest in much more research on the development of effective ameliorative interventions to help patients cope with quality of life threatening side-effects [ 33 ].”
BackgroundSelf-citation
The menopause specialist and breast cancer survivorship
Marsden, J. (2016) · Post Reproductive Health · doi:10.1177/2053369116668738 · Cited by 4
“In postmenopausal women both tamoxifen and aromatase inhibitors are associated with vasomotor symptoms, vaginal dryness, dyspareunia and arthralgia, which vary in prevalence between them.(11) If symptoms occur an indication of how troublesome they are likely to be can be gauged after about 3–6 months of treatment (sym…”
Background
The development and acceptability of symptom management quality improvement reports based on patient-reported data: an overview of methods used in PROSSES
Troeschel, A. N., Smith, T. G., Castro, K. M., Treiman, K., Lipscomb, J., McCabe, R. M., Clauser, S. B., Friedman, E. L., Hegedus, P. D., & Portier, K. M. (2016) · Quality of Life Research · doi:10.1007/s11136-016-1305-7 · Cited by 4
Association of single nucleotide polymorphisms of cytochrome P450 enzymes with experience of vasomotor, vaginal and musculoskeletal symptoms among breast cancer patients: a systematic review
Chan, C. W. H., Law, B. M. H., Ng, M. S. N., Wong, C. C. Y., Wong, C. W.-Y., Quinley, M., Orgusyan, J. M., Chow, K. M., & Waye, M. M. Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08268-8 · Cited by 4
“Given their potential negative impact on patients’ quality of life [47], more research may also be conducted on whether genetic variations of CYP genes are associated with these symptoms.”
Background
Tai Chi Chuan improves cytokine expression levels and quality of life in post chemotherapy breast cancer survivors
Cheung, M., & Loo, T. Y. (2021) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2021.10.3.0244 · Cited by 3
“Improvements to short term memory were also noted by patients of the study group, who complained of poor memory during chemotherapy treatment (24, 50, 51) .”
Background
The diaryl-imidazopyridazine anti-plasmodial compound, MMV652103, exhibits anti-breast cancer activity
Neumann-Mufweba, A., Kimani, S., Khan, S. F., Chibale, K., & Prince, S. (2021) · EXCLI journal · doi:10.17179/excli2021-4323 · Cited by 3
“It remains a global health burden primarily due to late diagnosis, the development of tumor drug resistance, poor therapy response and debilitating side effects associated with current therapies (Massarweh and Schiff, 2006; Cella and Fallowfield, 2008; Redig and McAllister, 2013).”
Background
Quality of life in Spanish postmenopausal breast cancer patients with localized disease who finish endocrine treatment: a prospective study
Arrarás, J. I., Illarramendi, J. J., Manterola, A., de la Cruz, S., Zarandona, U., Ibáñez, B., Salgado, E., Visus, I., Barrado, M., Teiejira, L., et al. (2023) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002178 · Cited by 3
Feasibility and acceptability of study methods and psychosocial interventions for body image among women diagnosed with breast cancer: A systematic review and narrative synthesis
Brunet, J., Price, J., Baillot, A., Dann, E., & Vani, M. F. (2024) · Psycho-Oncology · doi:10.1002/pon.6278 · Cited by 4
Patient‐reported outcome and survival in premenopausal hormone receptor‐positive breast cancer patients at moderate to high risk: comparing toremifene with aromatase inhibitor in a real‐world study
Yang, Y., Gan, F., Luo, T., Lin, Q., Yang, W., Chen, L., Zhang, W., Liu, Q., & Gong, C. (2024) · MedComm · doi:10.1002/mco2.698 · Cited by 3
The Management of Menopausal Symptoms in Women Following Breast Cancer: An Overview
Phua, C., & Baber, R. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0574-y · Cited by 3
Supportive care for patients with early breast cancer
García‐Estévez, L., Tusquets, I., Álvarez, I., Rodriguez, C. A., Fernández, Y., Seguí, M. Á., García-Mata, J., & Lluch, A. M. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0464-1 · Cited by 3
“These therapies are accompanied by a number of toxicities related to oestrogen withdrawal or antagonism, including hot fl ashes, night sweats, accelerated bone loss, and urogenital symptoms [ 59 ].”
Background
Factors associated with longer endocrine therapy use by South Carolina Medicaid-insured breast cancer survivors
Bedi, J. S., Mayo, R. M., Chen, L., Dickes, L., Sherrill, W. W., & Jones, K. O. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219835297 · Cited by 3
“Further research is also needed to test pharmacologic intervention strategies associated with longer ET duration in this study in addition to other nonpharmacologic interventions among low income populations.(38) Interventions aimed at enhancing the ET experience for breast cancer survivors to increase disease-free su…”
Background
Quality of Life in Breast Cancer Patients: An Overview of the Literature
(2012) · SpringerReference · doi:10.1007/springerreference_73494 · Cited by 3
Management of menopausal symptoms following treatment for hormone receptor positive breast cancer
McGrath, S., Pomeranc, A., Karmali, Y., Taylor, S., Morgan, A. A., Turner, L., & Armstrong, A. C. (2025) · British Journal of General Practice · doi:10.3399/bjgp.2025.0264 · Cited by 2
Venlafaxine reduces hot flashes in hormone receptor-positive breast cancer patients receiving tamoxifen: a prospective single-arm, open-label trial
Sato, R., Kamohara, R., Matsuo, T., Sawa, A., Okazaki, M., Hashimoto, S., Iguchi‐Manaka, A., Hara, H., Doki, K., Mukai, Y., et al. (2026) · Breast Cancer · doi:10.1007/s12282-026-01828-5 · Cited by 2
“Hot flashes during tamoxifen (TAM)-based adjuvant endocrine therapy after breast cancer surgery are a common adverse event [ 1 ], occurring in up to 86% of premenopausal patients, and are often more severe with concomitant luteinizing hormone-releasing hormone agonists (LHRHa) [ 2].”
Influential
The ethanolic extract of Aframomum angustifolium seeds protects against tamoxifen-induced side effects in rats with breast cancer
Makamwé, I., Ntentié, F. R., Mbong, M.-A. A., Kengne, A. P. N., Tienoue, H. M. F., Takuissu, G. R., Onsi, U. A. N., Zingue, S., & Oben, J. E. (2023) · Oriental Pharmacy and Experimental Medicine · doi:10.1007/s13596-023-00705-2 · Cited by 2
A survey of women diagnosed with breast cancer experiencing oncology treatment–induced hot flushes: identification of specific characteristics as predictors of hot flush occurrence, frequency, and severity
Gallagher, S., Johnstone, A., Livera, A. M. D., Marsh, D. J., & Walsh, S. (2024) · Journal of Cancer Survivorship · doi:10.1007/s11764-024-01647-7 · Cited by 2
“Critically, HFs can interfere with life-saving adherence to prescribed medication [4, 13–15].”
The role of microalgal extracts and their combination with tamoxifen in the modulation of breast cancer immunotherapy (Review)
Al-Shajrawi, O. M., Tarawneh, I. A. M., Din, T. A. D. A. T., & Afolabi, H. A. (2024) · Molecular and Clinical Oncology · doi:10.3892/mco.2024.2801 · Cited by 3
Environmental Concentrations of Polystyrene Nanoplastics Induce Low‐Dose Tamoxifen Toxicity Through Oxidative Stress in Caenorhabditis elegans
Wang, C., Yuan, J. J., Tang, Y., Zhu, C., & Zhuang, Z. (2025) · Journal of Applied Toxicology · doi:10.1002/jat.4760 · Cited by 2
“Through processes such as heating, photochemical reactions, and oxidation, this waste decomposes into nanoplastics (NPs; < 0.1 μm in diameter) (Canniff and Hoang 2018; Cella and Fallowfield 2008; Mitrano, Wick, and Nowack 2021; Song et al. 2017).”
Influential
Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada
Jerzak, K. J., Sehdev, S. R., Boileau, J.-F., Brezden‐Masley, C., Califaretti, N., Edwards, S. J., Gordon, J., Henning, J., LeVasseur, N., & Railton, C. (2025) · Current Oncology · doi:10.3390/curroncol32080444 · Cited by 2
“It is crucial to differentiate AEs related to CDK4/6 inhibitors from those caused by concomitant ET (e.g., AIs), such as myalgia, arthralgia, fatigue, and vasomotor symptoms, to prevent unnecessary treatment interruptions [58].”
Phytoestrogen Treatment for Menopausal Vasomotor Symptoms after Breast Cancer
Vogel, M., Franik, S., & Kiesel, L. (2023) · Breast Care · doi:10.1159/000529695 · Cited by 2
Effect of (GMODT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats
Ryu, E.-A., Kang, S.-J., Song, C., Lee, B.-H., Choi, S.-H., Han, C.-H., Lee, Y. J., & Ku, S. (2017) · 대한한의학회지 · doi:10.13048/jkm.17018 · Cited by 1
Rehabilitation and Survivorship
Bhargava, R., Chasen, M. R., & Feldstain, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-90990-5_39 · Cited by 2
Psychosocial issues in breast cancer
Fallowfield, L. J., & Jenkins, V. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-7020-4959-0.00016-3 · Cited by 2
Self-citation
Development of a Self-Report Instrument for Use in the Clinical Setting that Describes Symptoms related to Urogenital Atrophy in Women with Breast Cancer
Lester, J. L. (2008) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 2
Patient‐Reported Outcomes in Cancer
Stein, K., Smith, T. G., Bauer, J. E., Driscoll, D. L., & Cooper, D. L. (2017) · Wiley eBooks · doi:10.1002/9781119468868.ch31 · Cited by 2
Developing questions to assess and measure patients’ perceived survival benefit from adjuvant endocrine therapy in breast cancer: a mixed methods pilot study
Tawfik, B., Jacobson, K. A., Brown-Glaberman, U. A., Kosich, M., Horn, M. L. V., Nemunaitis, J. M., Dayao, Z. R., Pankratz, V. S., Sussman, A. L., & Guest, D. D. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01261-4 · Cited by 1
Coping With Side Effects: A Daily Diary Study in Women With Breast Cancer Living With Adjuvant Endocrine Therapy
Bierbauer, W., Scholz, U., Güth, U., Tausch, C., & Elfgen, C. (2024) · Psycho-Oncology · doi:10.1002/pon.70006 · Cited by 1
Cytotoxicity evaluation of hydro-alcoholic extract of Prangos pabularia Lindl root on breast cancer MCF-7 cell line
Fayazi, M., Sajjadi, M., & Mousavi, S. Y. (2024) · Journal of Herbmed Pharmacology · doi:10.34172/jhp.2025.52583 · Cited by 1
Implementing physical activity for individuals with cancer during treatment: protocol for the IMPACT implementation–effectiveness trial
Smith‐Turchyn, J., Sabiston, C. M., Edward, H., Richardson, J. L., Nayiga, B. K., Page, A., Brooks, D., & Mukherjee, S. D. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-101013 · Cited by 1
Acceptability of acceptance and commitment therapy for medication‐decision‐making and quality of life in women with breast cancer: A qualitative process evaluation
Green, S. M. C., Hall, L., Ellison, R., Clark, J. R., Wilkes, H., Hartley, S., Naik, J., Buckley, S., Hirst, C. M., Hartup, S. M., et al. (2025) · British Journal of Health Psychology · doi:10.1111/bjhp.12802 · Cited by 1
“A range of barriers to AET adherence have been reported, including the experience of unpleasant side effects (e.g., hot flushes, joint pain), psychological distress and unfavourable beliefs about AET (Cella & Fallowfield, 2008; Green et al., 2022; Jacobs et al., 2020; Lorizio et al., 2012; Toivonen”
Lessons Learned From Implementing a Culturally Tailored Virtual Support Program for Asian American Breast Cancer Survivors With Pain and Depression
Ryu, S., Kim, D., Chee, W., & Im, E. (2026) · Journal of Medical Internet Research · doi:10.2196/81187 · Cited by 1
Less endocrine therapy in HR+/HER2- breast cancer: a nationwide trend despite unchanged guidelines
Verreck, E. E. F., Postma, E. L., Oostergo, T., Meijer, J., Eijkelboom, A. H., Siesling, S., Rizopoulos, D., van Dalen, T., & Volders, J. H. (2025) · The Breast · doi:10.1016/j.breast.2025.104664 · Cited by 1
“Concordantly, there was a growing apprehension that previous broadening of adjuvant systemic therapy indications had led to overtreatment [2,9,11,12].”
Zorg aan borstkankerpatiënten tijdens de behandeling
Roorda-Lukkien, C., van der Veen, W. J., Lindeman, A., van der Meer, K., de Bock, G. H., & Jansen, L. (2011) · Huisarts en Wetenschap · doi:10.1007/s12445-011-0291-9 · Cited by 1
The Benefits of Physical Activity to Reduce Mortality in Postmenopausal Breast Cancer Patients: A Literature Review
Gumilang, T. J., & Hernawan, B. (2023) · Indonesian Journal of Cancer · doi:10.33371/ijoc.v17i1.917 · Cited by 1
Démystifier le cancer du sein
Wilkinson, A. N. (2023) · Canadian Family Physician · doi:10.46747/cfp.6907e149 · Cited by 1
Most prevalent side effects of aromatase inhibitors in the treatment of hormone-positive breast cancer: a scoping review
Zuffo, G. R., Ricardo, K. A., Comnisky, H., & Czepula, A. I. D. S. (2024) · Mastology · doi:10.29289/2594539420230033 · Cited by 1
“Nowadays, there are few studies about the pathogenesis of autoimmune diseases related to the use of aromatase inhibitors, but there is strong evidence that it is related with the effects of anastrozole in Th1/Th2 cellular balance, favoring the Th1 population (increase in interleukin-12 and IFN-y).”
BackgroundInfluential
Approaches to management of endocrine therapy–induced alopecia in breast cancer patients
Nguyen, M. A., & Kraft, S. L. (2025) · Supportive Care in Cancer · doi:10.1007/s00520-025-09258-3 · Cited by 2
“Endocrine-based therapy side effects can include hot flashes, arthritis-like joint pain, and hair thinning/loss on the scalp [3].”
Vaginale Östrogentherapie bei Mammakarzinompatientinnen
Mögele, M., Buchholz, S., Seitz, S., Lattrich, C., & Ortmann, O. (2012) · Gynäkologische Endokrinologie · doi:10.1007/s10304-011-0462-6 · Cited by 1
Workplace Mediation Procedures: A Case-Study of Transition Economies
Kalan, M., Razdevšek, M., & Suklan, J. (2017) · WSEAS TRANSACTIONS ON BUSINESS AND ECONOMICS · Cited by 1
Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
Gwark, S., Ahn, S. H., Noh, W. C., Lee, E. S., Jung, Y. S., Kim, L. S., Han, W., Nam, S. J., Gong, G., Kim, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.608207 · Cited by 1
bridging-the-gap-incorporating-exercise-evidence-into-clinical-practice-in-breast-cancer-care-in-ontario-a-pilot-randomized-control-trial-protocol/#
(2017) · Cancer Studies and Therapeutics · doi:10.31038/cst.2017222 · Cited by 1
The Experience of Cancer in Women
Stanton, A. L., & Yanez, B. R. (2013) · Wiley eBooks · doi:10.1002/9781394260454.ch20 · Cited by 1
Prävalenz der Amplifikation des Östrogen Rezeptor-Gens (ESR1) bei primären Mammakarzinomen und deren Lymphknotenmetastasen
Nottbohm, A.-K. (2013)
Hot Flashes in Relation to Breast Cancer Endocrine Therapy
Wall, A. V. D. (2014) · Home Health Care Management & Practice · doi:10.1177/1084822314542652
“, tamoxifen) is discontinued prematurely in a significant proportion of breast cancer patients because of intolerable side effects, especially hot flashes.(11-14) Selective serotonin release inhibitors have shown efficacy in the treatment of hot flashes, with the greatest response noted in the breast cancer population.”
Background
Adesão e persistência à terapia endócrina para o câncer de mama, fatores preditores e resultados relacionados
Brito, C. (2011) · Americanae (AECID Library)
The Impact of Access to Cancer Care on Adjuvant Endocrine Therapy Use Among Breast Cancer Survivors in Appalachia
Tan, X., Marshall, V., Camacho, F., Anderson, R. T., & Balkrishnan, R. (2015) · Value in Health · doi:10.1016/j.jval.2015.03.1244
Der Verlauf der Lebensqualität von Brustkrebspatientinnen in Abhängigkeit von Patientinnenmerkmalen und psychoonkologischem Angebot
Badtke, A. (2016) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5843
The Effect of Exemestane on Menopause-Specific Health-Related Quality of Life and a Comparison With Clinician-Reported Toxicities: an Analysis of the NCIC CTG MAP.2 Chemoprevention Trial
Causarano, N. (2012) · QSpace (Queen's University Library)
Sexuality and Fertility
Carter, J., Goldfarb, S. B., Sonoda, Y., Nelson, C. J., Dickler, M. N., & Mulhall, J. P. (2017) · Wiley eBooks · doi:10.1002/9781119468868.ch28
Nachsorge mit Rezidiv- und Metastasensuche und Therapiebegleitung
Beckmann, M. W., Kahmann, L., & Fasching, P. A. (2010) · Springer eBooks · doi:10.1007/978-3-642-12681-9_22
Dealing with vasomotor symptoms in patients with breast cancer, what options do we have?
Pilnik, S. (2018) · International Journal of Family & Community Medicine · doi:10.15406/ijfcm.2018.02.00083
The Potential for mHealth Interventions to Support Women with Breast Cancer after Active Treatment
Singleton, A. C., Raeside, R., Partridge, S. R., Sherman, K. A., Elder, E. E., & Redfern, J. (2019) · Research in Health Science · doi:10.22158/rhs.v4n2p112
Chinese Herbal Medicine to Alleviate Vasomotor Symptoms in Breast Cancer Survivors: A Study Protocol for a Randomised, Double Blind, Placebo Controlled, Multi Centre, Cross Over Trial
Porter, D. (2020) · American Journal of Biomedical Science & Research · doi:10.34297/ajbsr.2020.07.001117
The Primary Prevention of Breast Cancer: Risk Assessment, Genetic Screening, Chemoprevention, and Modifiable Risk Factors
Rusiecki, J. M., & Kwolek, D. S. (2020) · Springer eBooks · doi:10.1007/978-3-030-50695-7_17
Treatment Regimens and Survival Outcomes of Primary Neuroendocrine Carcinoma of Breast Compared with Infiltrating Ductal Carcinoma: A Large Propensity Score Matching StudyPreprint
Li, Q., Zhou, Y., Zhao, Y., & Ma, X. (2021) · Research Square · doi:10.21203/rs.3.rs-834840/v1
Literatur
(2013) · Elsevier eBooks · doi:10.1016/b978-3-437-31628-9.16001-8
Personalizing endocrine therapy for breast cancer using MRI
Ragusi, M. A. A.-D. D. (2022) · doi:10.33540/1248
Authorization of anastrazole to prevent breast cancer in postmenopausal women: a bad idea
Glynne, S., & Bluming, A. Z. (2024) · Climacteric · doi:10.1080/13697137.2023.2297889
“Anastrazole is associated with distressing and sometimes debilitating side effects including hot flushes, night sweats, insomnia, depression, arthralgia and genitourinary symptoms [5].”
Background
An interdisciplinary e-learning intervention for professionals working with breast cancer survivors and chronic pain: a realist evaluation
Slaghmuylder, Y., Lauwerier, E., Hecke, A. V., Crombez, G., Schelfout, S., Naert, E., & Pype, P. F. (2024) · Disability and Rehabilitation · doi:10.1080/09638288.2024.2443045
Computer-based Argumentation and PROMs Multi-objective Dynamic Management Decision Support System
He, M., Xiao, L., Pan, T., Zhu, R., Liu, Z., & Liu, M. (2024) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm62325.2024.10822599
Risk Factors for Infectious Disease Mortality in Breast Cancer: A Retrospective Cohort Study and Nomogram DevelopmentPreprint
Hemade, A., Akiki, M., Hallit, R. R., Dagher, C., & Hallit, S. R. (2025) · Research Square · doi:10.21203/rs.3.rs-6209450/v1
Vaginal health in breast cancer survivors: a practical clinical approach
Ram, M., Paluch–Shimon, S., Allweis, T. M., & Lev‐Sagie, A. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251344007
In reply
Glynne, S. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002670
To the editor
Armstrong, A. C., Bowen, R. L., Briggs, P., Palmieri, C., Mukherjee, A., & Williams, K. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002669
Sleep–wake disturbances and the cancer care continuum
Muench, A., Greeley, K. M., & Garland, S. N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13954-3.00027-9
EVALUATION OF HUMAN PROLACTIN, ITS ANTAGONIST, AND ANTAGONIST-BASED FUSION PROTEINS AS CHEMOPREVENTATIVE AND THERAPEUTIC AGENTS
Tomblyn, S. (2007) · TigerPrints (Clemson University)
Additional file 1 of Health-related quality of life in breast cancer patients: review of reviews from 2008 to 2018
Mokhatri-Hesari, P., & Montazeri, A. (2020) · Figshare · doi:10.6084/m9.figshare.13083326
Psychosocial Aspects of Breast Cancer: Managing the Emotional and Mental Health of Patients
Paul, A. A., Rao, K. M., Adusumilli, P. K., Kiran, P. K., Syed, J. M., Sastri, K. T., & Chalasani, S. H. (2026) · Springer eBooks · doi:10.1007/978-981-95-3682-5_25
Guía para el manejo de los síntomas menopáusicos en mujeres con cáncer de mama
Belardo, A., & Domingo, L. (2009) · Revista del Hospital Italiano de Buenos Aires · doi:10.51987/rev.hosp.ital.b.aires.v29i2.1045
Use of transdermal testosterone to treat menopausal symptoms in women with a history of breast cancer: a small, retrospective, open-label study
Glynne, S., Kamal, A., Neville, A. M., McColl, L., Reisel, D., & Newson, L. R. (2026) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002777
Monitoring Upper Extremity Function of Individuals With Breast Cancer: Development and Usability of the StrongArms-Cancer mHealth System
Smith‐Turchyn, J., Hvizd, J. L., Sykes, E. R., Mukherjee, S. D., Packham, T., McNeely, M. L., Moorlag, C., Shen, E., Isah, H., Anand, C., et al. (2026) · INQUIRY The Journal of Health Care Organization Provision and Financing · doi:10.1177/00469580261441759
Biomimetic nanoparticles for metastatic breast cancer: Advancing targeted drug delivery beyond conventional nanomedicine
Rehman, U., Dongsar, T. S., Dongsar, T. T., Hasan, N., Ahmed, F. J., & Kesharwani, P. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105495 · Cited by 1
Patient-reported changes in hot flash-related interference and quality of life after venlafaxine in breast cancer patients receiving tamoxifen: a prospective single-arm secondary analysisPreprint
Sato¹, R., Kamohara, R., Matsuo¹, T., Ueda-Sawa, A., Okazaki, M., Hashimoto², S., Akiko, I.-M., Doki, K., Mukai³, Y., Homma³, M., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9849787/v1
Kumatakenin as a multi-target putative inhibitor of breast cancer: Network pharmacology, molecular docking and MD simulation study via AKT1, EGFR and ESR1
Rangadal, D. N., Mavlankar, G. R., Baikar, P. P., Bhatu, M. N., Bansiwal, A. D., Chaudhari, A., & Patil, S. P. (2026) · Journal of the Indian Chemical Society · doi:10.1016/j.jics.2026.103134
Understanding Participant Characteristics of Who Is Accessing Breast Cancer Exercise Trials: A Scoping Review of Canadian Trials Over the Last 10 Years
Lacombe, K., Branderhorst, E., Curran, T., Campol, C., Pelczar, A., Boatsmith, M., Edward, H., & Smith‐Turchyn, J. (2026) · Physiotherapy Canada · doi:10.3138/ptc-2024-0120

Authors: Cella, D., & Fallowfield, L. J.
Affiliations: Northwestern University (US)
Brighton and Sussex Medical School (GB)
Corresponding author: Cella, David
ORCID: Cella, David
Fallowfield, Lesley J.
Venue: Breast Cancer Research and Treatment
Publisher: Springer Science and Business Media LLC
Published: 2007-09-18
Volume: 107
Issue: 2
Pages: 167-180
ISSN: 0167-6806 (ISSN-L)
1573-7217
DOI: 10.1007/s10549-007-9548-1
OpenAlex: W2034100757
Cited by: 286
References: 83
Citations by year: 2026: 9 · 2025: 17 · 2024: 16 · 2023: 22 · 2022: 20 · 2021: 17 · 2020: 14 · 2019: 16 · 2018: 15 · 2017: 19 · 2016: 17 · 2015: 15 · 2014: 9 · 2013: 14 · 2012: 17
FWCI: 0.88
Type: journal article
Language: en
Open access: green
figshare.com
Licence: cc-by
www.springer.com/tdm (tdm)
Locations: Breast Cancer Research and Treatment (publishedVersion)
PubMed (publishedVersion)
Sussex Research Online (University of Sussex) (submittedVersion)
Figshare (submittedVersion, cc-by)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Health Sciences › Medicine › Oncology › Cancer survivorship and care
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords: breast cancer, adjuvant endocrine therapy, aromatase inhibitors, tamoxifen, treatment-related adverse events, medication adherence, health-related quality of life, vasomotor symptoms, hot flashes, vaginal dryness, dyspareunia, joint pain, adverse event management, hormone receptor-positive breast cancer
MeSH terms: Aromatase, Breast Neoplasms, Clinical Trials as Topic, Endocrine System, Female, Humans, Medical Oncology, Patient Compliance, Quality of Life, Surveys and Questionnaires, Tamoxifen, Treatment Outcome, Chemotherapy, Adjuvant, Antineoplastic Agents, Hormonal, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks